Sökning: onr:"swepub:oai:DiVA.org:uu-54727" >
Olsalazine versus s...
Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis : A multicenter study
-
Nilsson, Å. (författare)
-
Danielsson, Å. (författare)
-
- Löfberg, R. (författare)
- Karolinska Institutet
-
visa fler...
-
Benno, P. (författare)
-
Bergman, L. (författare)
-
Fausa, O. (författare)
-
Florholmen, J. (författare)
-
Karvonen, A-L. (författare)
-
Kildebo, S. (författare)
-
Kollenber, B. (författare)
-
Lindberg, G. (författare)
-
- Lööf, Lars (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Gastroenterologigruppen, L Lööf
-
Stig, R. (författare)
-
Tanghoj, H. (författare)
-
visa färre...
-
(creator_code:org_t)
- 1995
- 1995
- Engelska.
-
Ingår i: American Journal of Gastroenterology. - 0002-9270 .- 1572-0241. ; 90:3, s. 381-387
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- OBJECTIVE: To compare the relapse-preventing effect and the frequency of adverse events of olsalazine and sulphasalazine in sulphasalazine-tolerant patients with ulcerative colitis. METHODS: Patients in remission, with at least two episodes of active disease during the last 5 yr, were randomized to 2 g of sulphasalazine or 1 g of olsalazine daily and were followed for 6-18 months. Relapse rates in the two groups were compared using frequency and life-table analysis. Sixty-nine patients with proctitis, 140 with left-sided colitis, and 113 with subtotal or total colitis were evaluated. RESULTS: In the intention-to-treat analysis, the failure rate (relapses plus withdrawals) was 54.7% in the olsalazine and 47.2% in the sulphasalazine group. In the per-protocol analysis excluding withdrawals, 44.7% relapsed in the olsalazine and 39.3% in the sulphasalazine group. Remission curves did not differ significantly, although at all time intervals the frequency of remission was slightly higher in the sulphasalazine group (p = 0.19 in the intention-to-treat analysis and p = 0.42 in the per-protocol analysis estimated by the log-rank test). Twelve patients (of whom five had diarrhea) in the olsalazine group versus eight patients in the sulphasalazine group discontinued the study because of side effects. CONCLUSION: The relapse-preventing effect of olsalazine and sulphasalazine in sulphasalazine-tolerant patients did not differ. Furthermore, the tolerability of olsalazine, particularly concerning diarrhea, appears to be better than previously reported.
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Nilsson, Å.
-
Danielsson, Å.
-
Löfberg, R.
-
Benno, P.
-
Bergman, L.
-
Fausa, O.
-
visa fler...
-
Florholmen, J.
-
Karvonen, A-L.
-
Kildebo, S.
-
Kollenber, B.
-
Lindberg, G.
-
Lööf, Lars
-
Stig, R.
-
Tanghoj, H.
-
visa färre...
- Artiklar i publikationen
-
American Journal ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet